On Demand Webinar

Fibroblasts can play a significant role in resistance to therapy. In the context of cancer cancer-associated fibroblasts (CAFs) in the TME have been associated with resistance to various therapeutic approaches. CAFs can contribute to therapy resistance through multiple mechanisms, including extracellular matrix remodeling, immune modulation, angiogenesis, and paracrine signaling. Understanding the intricate interactions between fibroblasts and cancer cells is crucial for developing more effective therapeutic strategies and overcoming resistance to cancer treatment.

In the pre-clinical stages of therapy testing, the use of clinically and biologically relevant models is essential. However, current preclinical tumor models often lack a comprehensive characterization of the TME. To address this limitation, Champions Oncology utilized transcriptomic data from its exclusive (TumorGraft) PDX models bank and analyzed the data with xCell computational method to identify molecular signatures predictive of fibroblast presence.

In this short AACR Poster QuickTake, we will take a deep dive into a novel gene signature that predicts fibroblast composition in the TME, allowing for an improved selection of PDX models for preclinical studies.

Meet Our Presenter:

Mara Gilardi, PhD, Immuno-oncology Subject Matter Expert, Champions Oncology

At the helm of Champions Oncology's immunology division, Mara synthesizes over 3 years of dedicated effort in translating cutting-edge research into clinical applications. Her core competencies include in-depth tumor microenvironment profiling with multiomics data, the development of ex vivo 2D-3D models and in vivo orthotopic models in immunodeficient and humanized animals, IHC and multiplex analysis and biomarker identification, which are instrumental in advancing our understanding and treatment of cancer.

Her mission is to bridge the gap between laboratory discoveries and patient care, driven by the ethical application of science and a commitment to improving clinical outcomes. Collaborating with industry leaders and our commercial and scientific teams, I am focused on fostering innovative R&D and marketing strategies while contributing to developing next-generation therapies.